<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088203</url>
  </required_header>
  <id_info>
    <org_study_id>PBRC 2013-049</org_study_id>
    <secondary_id>P50AT002776</secondary_id>
    <nct_id>NCT02088203</nct_id>
  </id_info>
  <brief_title>Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)</brief_title>
  <acronym>RT2</acronym>
  <official_title>Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Complex as a Dietary Supplement to Improve Carbohydrate Metabolism; Dosing, Safety and Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plants from the genus Artemisia, and specifically Artemisia dracunculus L. (Russian tarragon)&#xD;
      have had a long history of medicinal (health) and culinary (food) use and have been reported&#xD;
      as effective as a traditional treatments for diabetes in various parts of the world. The&#xD;
      overall objective of this study is to conduct early human investigation and to evaluate the&#xD;
      effect of nutritional supplementation with a well characterized extract of Artemisia&#xD;
      dracunculus L. The primary objectives would be to evaluate safety, tolerability and effective&#xD;
      dose in non-diabetic human subjects. Secondary objectives would assess metabolism of the&#xD;
      extract and evaluate effects on proposed mechanisms such as insulin secretion, lipid levels&#xD;
      and/or insulin resistance.&#xD;
&#xD;
      Single Oral Dose Evaluation&#xD;
&#xD;
      After completing a screening visit and meeting qualifications for the single oral dose&#xD;
      evaluation, subjects will receive three single doses (two different doses of the supplement&#xD;
      and one dose of placebo) on three separate test periods which are separated by a washout&#xD;
      period of at least 7 days. Each testing period requires an overnight stay on the inpatient&#xD;
      unit. The inpatient stay will be approximately 26 hours. The doses that will be used in the&#xD;
      study are 0.3, 1, 3, 10, 20 and 30 grams plus the placebo. The supplement and the placebo&#xD;
      will be mixed with sugar-free flavoring in water. There will be an opportunity to sample the&#xD;
      liquid drink during the screening visit.&#xD;
&#xD;
      Screening Visit 1 (about 1 hour) - Fasting (Nothing to eat or drink other than water for at&#xD;
      least 10 hours prior to appointment)&#xD;
&#xD;
        -  Sign informed consent if willing to participate&#xD;
&#xD;
        -  Body weight and height will be measured (body mass index will be calculated from these&#xD;
           measures)&#xD;
&#xD;
        -  Blood pressure, pulse and temperature will be measured&#xD;
&#xD;
        -  Physical exam and ECG (electrocardiogram)&#xD;
&#xD;
        -  Report any medications taken over the past 3 months&#xD;
&#xD;
        -  Blood draw (about 2 teaspoons) to assess overall health&#xD;
&#xD;
        -  Taste test&#xD;
&#xD;
      ALL PROCEDURES AND VISITS LISTED BELOW WILL BE REPEATED 3 TIMES. ALL TESTING WILL BE DONE FOR&#xD;
      EACH SINGLE DOSE TESTING PERIOD (1,2,3)&#xD;
&#xD;
        -  Testing Period 1: Day -3, Day 1, Day 2&#xD;
&#xD;
        -  7 Day Washout&#xD;
&#xD;
        -  Testing Period 2: Day -3, Day 1, Day 2&#xD;
&#xD;
        -  7 Day Washout&#xD;
&#xD;
        -  Testing Period 3: Day -3, Day 1, Day 2&#xD;
&#xD;
      Day -3 (about 4 hours) Fasting (Nothing to eat or drink other than water for at least 10&#xD;
      hours prior to appointment)&#xD;
&#xD;
        -  Blood pressure, pulse and temperature will be measured&#xD;
&#xD;
        -  An IV line will be placed in an arm vein for blood draw purposes and will remain there&#xD;
           throughout the testing.&#xD;
&#xD;
        -  A blood draw (approximately 2 teaspoons) will be done before and after dosing to assess&#xD;
           any changes in glucose or insulin.&#xD;
&#xD;
        -  An Oral Glucose Tolerance Test (OGTT) will be done A blood sample will be drawn from the&#xD;
           IV line, and then the subject will drink a sugar solution consisting of 75 grams of&#xD;
           glucose. Blood will be drawn at specific times after the drink is consumed. Each blood&#xD;
           sample will be about 1 tablespoon. (6 tablespoons total for the test). During the IV&#xD;
           procedure, a small amount of the subject's own blood (less than 1 teaspoon) will&#xD;
           immediately be returned into the vein through the IV after each specimen is collected.&#xD;
&#xD;
        -  Adverse events and changes in medication will be assessed by the staff&#xD;
&#xD;
        -  Meet with staff briefly about dietary intake and weight maintenance diets&#xD;
&#xD;
      Day 1 (Inpatient Stay- 26 hours) Fasting (Nothing to eat or drink other than water for at&#xD;
      least 10 hours prior to appointment)&#xD;
&#xD;
        -  Admission to the inpatient unit in the morning of the Day 1 visit. The subject will&#xD;
           remain on the unit overnight and be discharged on Day 2.&#xD;
&#xD;
        -  Blood pressure, pulse and temperature will be measured.&#xD;
&#xD;
        -  Randomization to the study dosing scheme will occur. Randomization is like flipping a&#xD;
           coin. The subject and the study staff will not know what dose the subject is receiving&#xD;
           or if the subject is receiving a placebo (inactive drink).&#xD;
&#xD;
        -  Single dose of extract given (either the supplement or placebo). The dose will be given&#xD;
           2 hours prior to the start of the OGTT. The extract will be in a powder form and will be&#xD;
           mixed with up to 8 ounces of liquid for the subject to drink.&#xD;
&#xD;
        -  An IV line will be placed in the arm vein for blood draw purposes and will remain there&#xD;
           throughout the testing.&#xD;
&#xD;
        -  OGTT as described above (at day -3).&#xD;
&#xD;
        -  A blood draw (approximately 2 teaspoons) before and after dosing will be done to assess&#xD;
           any changes in glucose or insulin. Blood draws will occur at 30, 60, 90, 120, 180, 240&#xD;
           minutes and 12 hours after dosing.&#xD;
&#xD;
        -  An ECG will be performed.&#xD;
&#xD;
        -  Adverse events and changes in medication will be assessed by the staff.&#xD;
&#xD;
        -  The subject will be asked to fast overnight until your blood work on Day 2.&#xD;
&#xD;
      Day 2 (Inpatient) Blood pressure, weight, pulse and temperature will be measured.&#xD;
&#xD;
        -  A physical exam will be done&#xD;
&#xD;
        -  A 24 hour post dose blood draw (approximately 1 teaspoon) will be done.&#xD;
&#xD;
        -  Study staff will schedule the next testing period if applicable and then the subject&#xD;
           will be discharged from the inpatient unit.&#xD;
&#xD;
      Multiple Oral Dose Evaluation&#xD;
&#xD;
      After completing a screening visit and meeting qualifications for the multiple oral dose&#xD;
      evaluation, subjects will receive three doses (two different doses of the supplement and one&#xD;
      dose of placebo) over three separate 21-day test periods that are each separated by a washout&#xD;
      period of at least 7 days. Each testing period involves 8 clinic visits. The doses that will&#xD;
      be used in the study are 0.3, 1, and 30 grams plus the placebo. The supplement and the&#xD;
      placebo will be mixed with sugar-free flavoring in water. There will be an opportunity to&#xD;
      sample the liquid drink during the screening visit.&#xD;
&#xD;
      Screening Visit 1 (about 1 hour) - Fasting (Nothing to eat or drink other than water for at&#xD;
      least 10 hours prior to appointment)&#xD;
&#xD;
        -  Sign informed consent if willing to participate&#xD;
&#xD;
        -  Body weight and height will be measured (body mass index will be calculated from these&#xD;
           measures)&#xD;
&#xD;
        -  Blood pressure, pulse and temperature will be measured&#xD;
&#xD;
        -  Physical exam and ECG (electrocardiogram)&#xD;
&#xD;
        -  Report any medications taken over the past 3 months&#xD;
&#xD;
        -  Blood draw (about 2 teaspoons) and urine collection to assess overall health&#xD;
&#xD;
        -  Meet with dietitian about normal dietary intake&#xD;
&#xD;
        -  Taste test&#xD;
&#xD;
      ALL PROCEDURES AND VISITS LISTED BELOW WILL BE REPEATED 3 TIMES. ALL TESTING WILL BE DONE FOR&#xD;
      EACH MULTIPLE DOSE TESTING PERIOD (1,2,3)&#xD;
&#xD;
        -  Testing Period 1: Day -3, Day 1, Day 3, Day 7, Day 10, Day 14, Day 17, Day 21&#xD;
&#xD;
        -  7 Day Washout&#xD;
&#xD;
        -  Testing Period 2: Day -3, Day 1, Day 3, Day 7, Day 10, Day 14, Day 17, Day 21&#xD;
&#xD;
        -  7 Day Washout&#xD;
&#xD;
        -  Testing Period 3: Day -3, Day 1, Day 3, Day 7, Day 10, Day 14, Day 17, Day 21&#xD;
&#xD;
      Day -3 (about 4 hours) Fasting (Nothing to eat or drink other than water for at least 10&#xD;
      hours prior to appointment)&#xD;
&#xD;
        -  Blood pressure, pulse, weight, and temperature will be measured&#xD;
&#xD;
        -  An IV line will be placed in an arm vein for blood draw purposes and will remain there&#xD;
           throughout the testing.&#xD;
&#xD;
        -  An Oral Glucose Tolerance Test (OGTT) will be done. A blood sample will be drawn from&#xD;
           the IV line, and then the subject will drink a sugar solution consisting of 75 grams of&#xD;
           glucose. Blood will be drawn at specific times after the drink is consumed. Each blood&#xD;
           sample will be about 1 tablespoon (3 tablespoons total for the test). During the IV&#xD;
           procedure, a small amount of the subject's own blood (less than 1 teaspoon) will&#xD;
           immediately be returned into the vein through the IV after each specimen is collected.&#xD;
&#xD;
        -  Females of child-bearing potential will have a urine pregnancy test&#xD;
&#xD;
        -  A dual-energy X-ray absorptiometry (DXA) scan will be performed using a whole-body&#xD;
           scanner. This scan measures the amount of bone, muscle, and fat in the body. The subject&#xD;
           will wear a hospital gown, remove all metal-containing objects, and lie down on a table&#xD;
           with legs held together by Velcro straps. A scanner emitting low-energy X rays and a&#xD;
           detector will pass along the body. The subject is asked to remain completely still for&#xD;
           the duration of the 10-minute scan.&#xD;
&#xD;
        -  Adverse events and changes in medication will be assessed by the staff&#xD;
&#xD;
        -  Meet with staff to assess dietary intake since prior visit&#xD;
&#xD;
      Day 1 (about 45 minutes) Non-fasting&#xD;
&#xD;
        -  Blood pressure, pulse, weight, and temperature will be measured.&#xD;
&#xD;
        -  Randomization to the study dosing scheme will occur. Randomization is like flipping a&#xD;
           coin. The subject and the study staff will not know what dose the subject is receiving&#xD;
           or if the subject is receiving a placebo (inactive drink).&#xD;
&#xD;
        -  The first dose of extract will be given (either the supplement or placebo). The subject&#xD;
           will be given instructions on how to take the extract at home. The extract will be in a&#xD;
           powder form to be mixed with up to 8 ounces of liquid to drink.&#xD;
&#xD;
        -  Adverse events and changes in medication will be assessed by the staff.&#xD;
&#xD;
      Days 3, 10, and 17 (about 30 minutes each) Non-fasting&#xD;
&#xD;
        -  Blood pressure, pulse, weight, and temperature will be measured.&#xD;
&#xD;
        -  Compliance with extract dosing will be assessed and additional extract dispensed as&#xD;
           needed.&#xD;
&#xD;
        -  Adverse events and changes in medication will be assessed by the staff.&#xD;
&#xD;
      Days 7, 14, and 21 (about 6 hours each) Fasting (Nothing to eat or drink other than water for&#xD;
      at least 10 hours prior to appointment)&#xD;
&#xD;
        -  Blood pressure, pulse, weight, and temperature will be measured.&#xD;
&#xD;
        -  Compliance with extract dosing will be assessed and additional extract dispensed as&#xD;
           needed (except at Day 21 when dosage is stopped).&#xD;
&#xD;
        -  Adverse events and changes in medication will be assessed by the staff.&#xD;
&#xD;
        -  Physical exam and ECG (electrocardiogram) will be performed.&#xD;
&#xD;
        -  An IV line will be placed in the arm vein for blood draw purposes and will remain there&#xD;
           throughout the testing.&#xD;
&#xD;
        -  OGTT as described above (at Day -3).&#xD;
&#xD;
        -  A blood draw (approximately 3 tablespoons) before and after dosing will be done to&#xD;
           assess any changes in glucose or insulin. Blood draws will occur at 0, 30, 60, 90, 120,&#xD;
           180, and 240 minutes after dosing.&#xD;
&#xD;
        -  Urine samples will be collected throughout the test day to measure the body's response&#xD;
           to the daily doses of extract.&#xD;
&#xD;
        -  Meet with dietitian to assess food intake to assure it has not changed from normal diet.&#xD;
&#xD;
        -  At Day 21 only, a DXA scan will be performed as described above (at Day -3). Females of&#xD;
           child-bearing potential will have a urine pregnancy test prior to the DXA scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of bioactive components from the Russian Tarragon Nutrasorb in the blood and urine</measure>
    <time_frame>on average weekly for 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance measured with an OGTT</measure>
    <time_frame>on average weekly for 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabetes Prevention</condition>
  <arm_group>
    <arm_group_label>Single Dose Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose 1</intervention_name>
    <description>Russian Tarragon Nutrasorb 0.3 g</description>
    <arm_group_label>Multiple Dose Sequence 1</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 2</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 3</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 7</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 8</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 9</arm_group_label>
    <arm_group_label>Single Dose Sequence 1</arm_group_label>
    <arm_group_label>Single Dose Sequence 2</arm_group_label>
    <arm_group_label>Single Dose Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose 2</intervention_name>
    <description>Russian Tarragon Nutrasorb 1 g</description>
    <arm_group_label>Multiple Dose Sequence 1</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 2</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 3</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 4</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 5</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 6</arm_group_label>
    <arm_group_label>Single Dose Sequence 1</arm_group_label>
    <arm_group_label>Single Dose Sequence 2</arm_group_label>
    <arm_group_label>Single Dose Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose 0</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Multiple Dose Sequence 1</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 2</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 3</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 4</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 5</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 6</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 7</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 8</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 9</arm_group_label>
    <arm_group_label>Single Dose Sequence 1</arm_group_label>
    <arm_group_label>Single Dose Sequence 2</arm_group_label>
    <arm_group_label>Single Dose Sequence 3</arm_group_label>
    <arm_group_label>Single Dose Sequence 4</arm_group_label>
    <arm_group_label>Single Dose Sequence 5</arm_group_label>
    <arm_group_label>Single Dose Sequence 6</arm_group_label>
    <arm_group_label>Single Dose Sequence 7</arm_group_label>
    <arm_group_label>Single Dose Sequence 8</arm_group_label>
    <arm_group_label>Single Dose Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose 3</intervention_name>
    <description>Russian Tarragon Nutrasorb 3 g</description>
    <arm_group_label>Single Dose Sequence 4</arm_group_label>
    <arm_group_label>Single Dose Sequence 5</arm_group_label>
    <arm_group_label>Single Dose Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose 4</intervention_name>
    <description>Russian Tarragon Nutrasorb 10 g</description>
    <arm_group_label>Single Dose Sequence 4</arm_group_label>
    <arm_group_label>Single Dose Sequence 5</arm_group_label>
    <arm_group_label>Single Dose Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose 5</intervention_name>
    <description>Russian Tarragon Nutrasorb 20 g</description>
    <arm_group_label>Single Dose Sequence 7</arm_group_label>
    <arm_group_label>Single Dose Sequence 8</arm_group_label>
    <arm_group_label>Single Dose Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dose 6</intervention_name>
    <description>Russian Tarragon Nutrasorb 30 g</description>
    <arm_group_label>Multiple Dose Sequence 4</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 5</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 6</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 7</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 8</arm_group_label>
    <arm_group_label>Multiple Dose Sequence 9</arm_group_label>
    <arm_group_label>Single Dose Sequence 7</arm_group_label>
    <arm_group_label>Single Dose Sequence 8</arm_group_label>
    <arm_group_label>Single Dose Sequence 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are an overall healthy adult&#xD;
&#xD;
          -  Are male or female, ages 18-65 at time of consent&#xD;
&#xD;
          -  Are female and of childbearing potential, you must agree to use one of the approved&#xD;
             contraception method [(i.e., barrier method, intrauterine and cervical devices, oral&#xD;
             contraceptives, hormonal injections (Depo ProveraÂ®), condoms with spermicidal gel or&#xD;
             foam, contraceptive patch (Ortho Evra), diaphragm, or abstinence)], prior to the start&#xD;
             of dosing to sufficiently minimize the risk of pregnancy at that point. Female&#xD;
             subjects must agree to use contraception until the follow-up visit.&#xD;
&#xD;
          -  Have a BMI within the range 18.5-40 kg/m2 (this is a measure of your height to weight&#xD;
             ratio).&#xD;
&#xD;
          -  Are capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Have no significant cardiac, pulmonary, gastrointestinal, hepatic, renal,&#xD;
             hematological, endocrine, neurological and psychiatric disease&#xD;
&#xD;
          -  Have overall normal clinical laboratory tests as deemed by the physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a prior history of Type 1 or 2 diabetes&#xD;
&#xD;
          -  Are a female who is pregnant or lactating.&#xD;
&#xD;
          -  Are taking certain medications (these will be reviewed with you by the study staff).&#xD;
&#xD;
          -  Are anticipating or planning to have surgery during the study period.&#xD;
&#xD;
          -  Are a current smoker or have smoked within the previous 6 months.&#xD;
&#xD;
          -  Have had a weight change of more than 5% in the last 2 months.&#xD;
&#xD;
          -  Are taking prescription or over the counter medications or supplements for weight&#xD;
             loss.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer C Rood, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Jennifer C. Rood</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02088203/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

